31 results about "Gene Expression Inhibitor" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a GABRD gene expression inhibitor in preparation of a medicine for treating hepatocellular carcinoma. The GABRD gene expression inhibitor is an adeno-associated virus AAV recombinant vector, a WP1066 or IL-10R1 neutralizing antibody for targeted inhibition of GABRD gene expression. Experiments in the invention show that the three GABRD gene expression inhibitors can significantly inhibit tumor growth of mice with hepatocellular carcinoma tumors.

The application discloses application of a circFOXO3 gene expression inhibitor in preparation of a medicine for preventing and / or treating periodontitis, and belongs to the technical field of medicines.The siRNA of the circFOXO3 is adopted to down-regulate the expression of the circFOXO3 gene, so that the expression amount of ITGB6 is up-regulated, the activation of TGF-beta 1 is promoted, and then the occurrence and development of periodontitis are inhibited.The siRNA of the cholesterol-modified circFOXO3 can increase the stability and in-vivo metabolic time of the siRNA.

The present invention relates to a method for treating cancer, comprising administering a composition comprising γδ T cells treated with an inhibitor of XBP1 gene expression or an inhibitor of XBP1 protein expression or activity. The γδ T cells, in which the XBP1 gene is deficient or the XBP1 protein activity is inhibited, exhibit enhanced antitumor activity in a tumor microenvironment characterized by endoplasmic reticulum (ER) stress, as compared to unmodified γδ T cells. Accordingly, the modified γδ T cells are effective for use in cancer treatment.

The invention belongs to the technical field of medicines, and discloses a KRT6A gene expression inhibitor and application thereof in preparation of a medicine for treating gemcitabine drug-resistant pancreatic cancer. Researches find that KRT6A is abnormally highly expressed in pancreatic cancer and is closely related to poor curative effect of gemcitabine. According to the inhibitor, KRT6A gene expression is specifically silenced in a tumor targeted delivery mode, expression and functions of nucleoside transporter ENT1 are recovered, and cellular uptake of gemcitabine is enhanced; the compound can inhibit MIF-CD44 / CD74 signal axis mediated tumor-associated macrophage M2 type polarization, reduce exogenous pyrimidine nucleoside supply and weaken competitive inhibition of the compound and gemcitabine in nucleoside transport and metabolic pathways, so that effective uptake and efficacy of gemcitabine in pancreatic cancer cells are synergistically improved, and gemcitabine drug resistance is reversed or relieved. The invention provides a new and effective technical scheme for clinical treatment of gemcitabine drug-resistant pancreatic cancer.

The present application relates to the field of medicine, and particularly relates to application of SUCNR1 gene expression inhibitor in preparation of a drug for improving heart failure. The SUCNR1 gene expression inhibitor comprises a SUCNR1 gene knockout reagent, and the SUCNR1 gene knockout reagent is siRNA. The present application finds that the SUCNR1 expression level is highly expressed in a mouse heart failure model, and the siRNA technology is used to respectively transfect myocardial cells by siRNA, and the siRNA is used to knock down and reduce the SUCNR1 protein level in cells or heart tissues, so as to determine the effect of SUCNR1 on the mouse heart function; the biological information analysis method is used to analyze and predict the target gene participating in the heart mitochondrial function damage which can be regulated by SUCNR1, and then the siRNA is used to knock down the SUCNR1, so as to determine the regulation effect of the siRNA on the downstream gene, and the mechanism is determined, so that the SUCNR1 becomes an important target point for treating heart failure in the heart.

The invention belongs to the technical field of biological medicines, and particularly discloses a nano-drug for oral cancer as well as a preparation method and application of the nano-drug. The nano-drug provided by the invention is a drug-loaded mesoporous polydopamine nano-particle wrapped by a lipidosome modified by RGD peptide; wherein the load components of the mesoporous polydopamine nanoparticles comprise a cis-platinum drug and an RBMX gene expression inhibitor. The molecular RBMX related to regulation and control of oral cancer progress and cis-platinum drug resistance is screened, a nano biomimetic material drug loading system is constructed to load si-RBMX and cis-platinum to synergistically resist oral cancer treatment, and a novel nano drug with strong targeting property, good biological safety and excellent tumor lethality is obtained. The invention also provides a preparation method and application of the nano-drug.

The invention relates to the technical field of medicine, in particular to application of a CPN1 gene expression inhibitor in preparation of a medicine for treating myocardial infarction, an ROS response type medicine delivery system for treating myocardial infarction and a preparation method and application of the ROS response type medicine delivery system. According to the application, the siRNA for silencing the CPN1 gene is used as an active component for preparing the medicine for treating myocardial infarction for the first time; furthermore, specific siRNA and ROS respond to the DMPE-PEG-APPA nano-micelle entrapped siRNA, so that selective drug release and efficient silencing of the focus are realized, and a relatively good myocardial protection effect is obtained. According to the delivery system, an ROS response type carrier material DMPE-PEG-APPA is self-assembled to form nano-micelles, efficient silence siRNA aiming at a CPN1 gene is entrapped, and the delivery system has good structural stability and ROS responsiveness and can be specifically split to release drugs in a high ROS environment of a myocardial infarction focus.

The invention relates to the technical field of biology, in particular to a method for reducing listeria monocytogenes infection by interfering host MIC19 gene expression. Specifically, the invention is based on the discovery that interference of MIC19 gene expression in cells can cause reduction of infection ability and intracellular proliferation ability of Listeria monocytogenes. The result shows that the expression quantity imbalance of the endogenous MIC19 gene in the cell is not beneficial to the infection and proliferation of the listeria monocytogenes. On the basis, on one hand, the invention provides application of an MIC19 gene expression inhibitor in preparation of a medicine for reducing listeria monocytogenes infection. On the other hand, the invention provides a method for reducing the infection of the cells with the Listeria monocytogenes in vitro and the cells obtained by the method.

The present disclosure provides methods of treating HBV infection using combination therapy, as well as related kits and compositions for use. Components of the combination therapy include an HBV gene expression inhibitor or an agent that reduces HBV antigen loading, and an anti-HBV antibody.

The application discloses antisense nucleotides and purposes thereof, a cell line for knocking down or overexpressing a FUNDC1 gene, a gene expression inhibitor and a medicine, and belongs to the technical field of biological prevention and control. The technical scheme is as follows: antisense nucleotides of the FUNDC1 gene, wherein the nucleotide sequence of the antisense nucleotides is shown as SEQ ID NO. 1. The application provides antisense nucleotides of the FUNDC1 gene, which can inhibit the expression of the FUNDC1 gene. More importantly, in the case that the known mitochondrial autophagy is inhibited and the proliferation of the influenza virus is promoted, it is unexpectedly found that the inhibition of the expression of the FUNDC1 gene can inhibit the mitochondrial autophagy and inhibit the proliferation of the H5N1 influenza virus.

The invention relates to application of a USP18 gene as a drug target in screening drugs for preventing, relieving and / or treating myocardial ischemia-reperfusion injury. Compared with a mouse without the USP18 gene knockout, the mouse with the USP18 gene knockout has the advantages that the myocardial infarction area is obviously reduced, the mitochondrial dysfunction is obviously improved, the cardiac contraction function is obviously enhanced, and the long-term myocardial fibrosis degree is reduced. The result shows that USP18 gene knockout can significantly alleviate the pathological process of myocardial ischemia reperfusion injury. Therefore, the USP18 gene is used as a target, and the screened USP18 gene expression inhibitor can be used for preparing medicines for preventing, relieving and / or treating myocardial ischemia-reperfusion injury. Compared with an Anti-NC mouse, the myocardial infarction area of the Anti-PTEN-L mouse is remarkably reduced, the mitochondrial dysfunction is remarkably improved, the cardiac contraction function is remarkably enhanced, and the long-term myocardial fibrosis degree is reduced. Therefore, the PTEN-L neutralizing antibody can also be used for preparing the medicine for preventing, relieving and / or treating the myocardial ischemia-reperfusion injury.

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies include an inhibitor of HBV gene expression or an agent that reduces HBV antigenic load, and an anti-HBV antibody.

Provided herein are systems comprising one or both of cytokines and / or synthetic pathway activators. Also provided herein are systems comprising one or more suppressors of gene expression, and one or both of cytokines and / or synthetic pathway activators. Also provided are systems of chimeric priming receptors that bind ALPG and / or ALPP, chimeric antigen receptors that bind MSLN, and at least one of one or more suppressors of gene expression, and / or one or both of cytokines and / or synthetic pathway activators; cells expressing such systems; and methods of use thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a GABRD gene expression inhibitor in preparation of a medicine for inhibiting lung metastasis of liver cancer cells. The GABRD gene expression inhibitor is a CRISPR-Cas9 tool for targeted knockout or knockdown of a GABRD gene and a related biological reagent, and a sense strand sequence of sgRNA of the CRISPR-Cas9 tool is as shown in SEQ ID NO: 1. Experiments prove that lung metastasis of liver cancer cells can be remarkably inhibited by inhibiting expression of the GABRD gene.

The application belongs to the technical field of genetic engineering and cardiovascular disease treatment, and specifically discloses application of an expression inhibitor of a TSPAN4 gene in preparation of a drug for treating cardiovascular diseases and the drug containing the expression inhibitor of the TSPAN4 gene. The application first constructs a carotid artery injury mouse model, and research finds that the expression absence of TSPAN4 has a significant improvement effect on intimal neogenesis. Further, the expression of the TSPAN4 gene is inhibited through siRNA interference RNA technology targeting the TSPAN4 gene, and it is found that after being treated by human h-siTSPAN4, the phenotype of smooth muscle cells can be changed, and the purpose of treating cardiovascular diseases can be achieved. The method of the application can inhibit the expression of the TSPAN4 gene by delivering siRNA, so as to inhibit the proliferation and migration of abnormal smooth muscle cells and reduce the development of cardiovascular diseases.

The invention discloses a novel application of a GRB2 gene, namely a preparation for enhancing tumor cell drug sensitivity is screened in order to inhibit the expression of the GRB2 gene. According to the application disclosed by the invention, the expression of the GRB2 gene in tumor cells is inhibited by virtue of an RNA interference technology, so that the phosphorylation level of key protein in a PI3K / Akt / mTOR signal channel can be remarkably reduced, the IC50 value of the tumor cells to chemotherapeutic drugs is reduced, and the apoptosis rate of the tumor cells is increased. Meanwhile, the relevance between GRB2 regulation and a PI3K / Akt signal channel is verified, when an Akt activator SC79 is used for reversing the inhibition effect of the signal channel, the drug sensitization effect mediated by GRB2 regulation is blocked, and it is proved that GRB2 affects the molecular mechanism of tumor cell drug sensitivity by regulating the PI3K / Akt / mTOR channel. The invention provides a new solution thought for the tumor chemotherapy drug resistance problem, and has important clinical transformation value.

The invention relates to the technical field of biology, in particular to a method for reducing listeria monocytogenes infection by inhibiting host CypD protein synthesis. Specifically, the invention finds that the proliferation of the listeria monocytogenes in cells can be obviously reduced and the growth activity of the cells is not influenced by inactivating or inhibiting the expression of the CypD protein (the coding gene is PPIF), and a basis is provided for preventing and treating the infection of the listeria monocytogenes by clinically utilizing a PPIF gene expression inhibitor or a CypD protein synthesis inhibitor. On the basis, on one hand, the invention provides application of a PPIF gene expression inhibitor or a CypD protein synthesis inhibitor in reduction of listeria monocytogenes infection. On the other hand, the invention provides an application of a vector for inactivating the PPIF gene or reducing expression of the PPIF gene or an engineered cell or a recombinant microorganism containing the vector in reduction of Listeria monocytogenes infection.

The invention relates to application of an ESRRA gene expression inhibitor in preparation of medicines for preventing and treating atherosclerosis, and belongs to the field of biological medicines. In order to solve the problem that existing drugs cannot specifically regulate and control phenotypic changes of VSMCs in atherosclerosis, the invention provides application of an ESRRA gene expression inhibitor in preparation of drugs for preventing and treating atherosclerosis, and the ESRRA gene expression inhibitor is a small nucleic acid gene silencing preparation and / or a small molecule compound AM251. The ESRRA gene expression inhibitor provided by the invention can remarkably inhibit abnormal proliferation and migration behaviors of vascular smooth muscle cells, block pathological transformation of the vascular smooth muscle cells to synthetic phenotypes, and remarkably lower the expression level of PCSK9 protein in the liver, so that the concentration of low-density lipoprotein cholesterol in plasma is effectively reduced, formation and development of new plaques are inhibited, and the ESRRA gene expression inhibitor has a good application prospect. The method has the advantage of multi-target and multi-channel synergistic effect.

The disclosure firstly discovers that plakophilin 1 (PKP1) can be used as a marker for diagnosis / prognosis of squamous carcinoma of organ (such as pancreas) adenocarcinoma, and relates to application of PKP1 (such as DNA, mRNA or protein thereof) as the marker for diagnosis / prognosis of squamous carcinoma of organ (such as pancreas) adenocarcinoma. The present disclosure also relates to a composition for treating squamous carcinoma of adenocarcinoma of an organ (e.g., pancreas) using as an active ingredient a PKP1 gene expression inhibitor (e.g., siRNA, an antibody, a gene editing composition targeting the PKP1 gene (e.g., a CRISPR-Cas composition, etc.), and a method for diagnosing squamous carcinoma of adenocarcinoma by measuring PKP1.

This invention relates to the application of an IGF-1R gene expression inhibitor in the preparation of drugs for delaying aging and improving age-related diseases. Using gene interference technology, siRNA targeting the IGF-1R gene is designed and chemically modified to inhibit its expression by suppressing transcription and downstream signaling pathways. Compared with middle-aged control mice, the hair condition, motor ability, and learning and memory functions of the middle-aged mice were significantly improved under IGF-1R inhibition, even resembling those of adult mice. This indicates that the IGF-1R gene is an important factor in delaying aging. Therefore, designing drugs that inhibit IGF-1R expression can provide a new direction for the development of anti-aging and age-related disease prevention drugs, showing great promise for anti-aging target applications.

The application discloses application of a SUCNR1 gene expression inhibitor in preparation of a product for preventing or treating a dairy cow dystocia. The application provides application of a substance taking a SUCNR1 protein as an inhibition target and / or a substance taking a SUCNR1 gene as an inhibition target in preparation of a product. The application of the product is as follows: promoting trophoblast cell apoptosis; inhibiting macrophage M2 type polarization; promoting trophoblast cell apoptosis by inhibiting macrophage M2 type polarization. The inventors of the application find that silencing the SUCNR1 gene can inhibit a PI3K signal pathway, thereby inhibiting macrophage M2 type polarization, thereby promoting trophoblast cell apoptosis, thereby helping to solve the problem of dystocia.

The invention relates to application of DHCR24 related to diagnosis, treatment and prognosis of cervical cancer. The application comprises the application of the DHCR24 gene expression inhibitor in preparation of drugs for preventing, relieving and / or treating cervical cancer, the application of a reagent for detecting the DHCR24 gene expression level in preparation of products for diagnosis or prognosis of cervical cancer, a cervical cancer risk assessment or prognosis device and a cervical cancer risk assessment or prognosis instrument. The invention finds that 24-dehydrocholesterol reductase (DHCR24) is highly expressed in cervical cancer cells and is related to poor prognosis of cervical cancer; proliferation, migration and invasion of cervical cancer cells and dryness of tumor cells can be inhibited by inhibiting expression of DHCR24, and apoptosis of the cervical cancer cells is promoted. Therefore, DHCR24 can be used as a diagnosis and prognosis marker and a treatment target of cervical cancer, and has a huge application prospect.

The present invention relates to a pharmaceutical composition for preventing or treating sepsis, comprising an miR-223 gene expression inhibitor. The pharmaceutical composition comprising an miR-223 gene expression inhibitor, according to the present invention, inhibits cell death, and thus has the effect of preventing or treating sepsis.

The present specification provides a pharmaceutical composition for preventing or treating gastric cancer, comprising, as an active ingredient, a protein activity inhibitor or gene expression inhibitor for at least one of SHMT1, TYMS, MTHFD1, and DHFR, wherein the protein activity inhibitor is at least one of a compound, a peptide, a peptidomimetic, a substrate analog, an aptamer, and an antibody that specifically bind to a protein, and the gene expression inhibitor is at least one of an antisense nucleotide, RNAi, siRNA, miRNA, shRNA, and a ribozyme that complementarily bind to mRNA of a gene.

The invention discloses application of an expression inhibitor of a SiToll1 gene in prevention and treatment of solenopsis invicta. According to the invention, dsRNA is designed and expressed aiming at the Solenopsis invicta Toll1 (SiToll1) gene and is fed to the Solenopsis invicta worker ant, so that the feeding of the dsRNA can cause the down-regulation of the SiToll1 gene expression, the activity distance, the movement rate and the foraging intensity of the foraging type worker ant are obviously reduced, and meanwhile, the foraging type worker ant shows a phenomenon that the foraging type worker ant is transformed to a young breeding type worker ant. The expression inhibitor of the SiToll1 gene can be utilized to change individual division of labor of the solenopsis invicta worker ants, so that foraging type worker ants are converted into juvenile type worker ants to achieve the purpose of controlling ant colony diffusion, and control of the solenopsis invicta is realized. The invention provides a new target for the control of the solenopsis invicta, is beneficial to the development of solenopsis invicta control products, and reduces the harm of the solenopsis invicta.

The present invention relates to a pharmaceutical composition and the like for lowering blood cholesterol, preventing or treating cardiovascular diseases and reducing inflammation, containing, as an active ingredient, an inhibitor of binding between CAP1 and PCSK9, an inhibitor of binding between CAP1 and resistin, or a CAP1 gene expression inhibitor. The present invention can lower the level of blood LDL-cholesterol by inhibiting the binding of CAP1 and PCSK9, the binding of CAP1 and resistin or the expression of a CAP1 gene. Therefore, the present invention can be effectively used as a pharmaceutical composition and the like for treating abnormal blood cholesterol levels and various cardiovascular diseases caused thereby, such as dyslipidemia, stroke, arteriosclerosis, and the like, and for inhibiting inflammation.

The invention belongs to the technical field of medicines, and discloses application of an AMPD3 gene expression inhibitor in preparation of a medicine for preventing, relieving and / or treating polycystic ovarian syndrome. The AMPD3 gene expression inhibitor is a nucleic acid molecule targeting an AMPD3 gene sequence or a recombinant vector containing the nucleic acid molecule. According to the invention, ovarian morphological abnormality and reproductive endocrine metabolism disorder are improved by inhibiting AMPD3 gene expression, reducing ovarian granular cell ferroptosis level, up-regulating GPX4 expression and reducing MDA level. The invention provides a new treatment strategy for patients with polycystic ovarian syndrome.

To find new drugs that are effective in improving facial conditions from a novel perspective, such as suppressing the expression of VEGF-A signaling-related protein genes. [Solution] This disclosure provides an inhibitor of VEGF-A signaling-related protein gene expression containing 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof as an active ingredient. Furthermore, this disclosure provides a screening method for VEGF-A signaling-related protein gene expression inhibitors, comprising contacting candidate compounds with skin cells and selecting an inhibitor of VEGF-A signaling-related protein gene expression based on the degree of suppression of VEGF-A signaling-related protein gene expression in the skin cells.

The invention relates to an angiopoietin-like protein 7 inhibitor and application thereof, and belongs to the technical field of biological medicine. The invention provides an ANGPTL7 gene expression inhibitor and application thereof in order to solve the problems that existing heart failure treatment drugs mostly indirectly regulate a neuroendocrine system and are difficult to accurately intervene in myocardial fibrosis and reconstruct a core mechanism. The inhibitor is specific siRNA (small interfering Ribonucleic Acid) targeting ANGPTL7. According to the scheme, by directly inhibiting a key disease promoting factor ANGPTL7 in heart failure, myocardial cell damage can be effectively relieved, myocardial fibrosis is inhibited, and the heart function is improved. The invention provides a brand-new targeted treatment strategy with a clear mechanism for prevention and treatment of heart failure, and has an important clinical application prospect.